Biotech Values

[genisi]

April 19 (Bloomberg) -- Astellas Pharma Inc. said it won’t raise its $3.5 billion unsolicited bid for OSI Pharmaceuticals Inc. after the target company won approval for expanded use of its main drug.

http://www.bloomberg.com/apps/news?pid=20601202&sid=a6gK1admzZ2Q#